Cargando…

(1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug

(1)H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1](6+) as potential anticancer drug. Human ovarian cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermathen, Martina, Paul, Lydia E. H., Diserens, Gaëlle, Vermathen, Peter, Furrer, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449131/
https://www.ncbi.nlm.nih.gov/pubmed/26024484
http://dx.doi.org/10.1371/journal.pone.0128478
_version_ 1782373816388812800
author Vermathen, Martina
Paul, Lydia E. H.
Diserens, Gaëlle
Vermathen, Peter
Furrer, Julien
author_facet Vermathen, Martina
Paul, Lydia E. H.
Diserens, Gaëlle
Vermathen, Peter
Furrer, Julien
author_sort Vermathen, Martina
collection PubMed
description (1)H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1](6+) as potential anticancer drug. Human ovarian cancer cells (A2780), the corresponding cisplatin resistant cells (A2780cisR), and human embryonic kidney cells (HEK-293) were each incubated for 24 h and 72 h with [1](6+) and compared to untreated cells. Different responses were obtained depending on the cell type and incubation time. Most pronounced changes were found for lipids, choline containing compounds, glutamate and glutathione, nucleotide sugars, lactate, and some amino acids. Possible contributions of these metabolites to physiologic processes are discussed. The time-dependent metabolic response patterns suggest that A2780 cells on one hand and HEK-293 cells and A2780cisR cells on the other hand may follow different cell death pathways and exist in different temporal stages thereof.
format Online
Article
Text
id pubmed-4449131
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44491312015-06-09 (1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug Vermathen, Martina Paul, Lydia E. H. Diserens, Gaëlle Vermathen, Peter Furrer, Julien PLoS One Research Article (1)H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1](6+) as potential anticancer drug. Human ovarian cancer cells (A2780), the corresponding cisplatin resistant cells (A2780cisR), and human embryonic kidney cells (HEK-293) were each incubated for 24 h and 72 h with [1](6+) and compared to untreated cells. Different responses were obtained depending on the cell type and incubation time. Most pronounced changes were found for lipids, choline containing compounds, glutamate and glutathione, nucleotide sugars, lactate, and some amino acids. Possible contributions of these metabolites to physiologic processes are discussed. The time-dependent metabolic response patterns suggest that A2780 cells on one hand and HEK-293 cells and A2780cisR cells on the other hand may follow different cell death pathways and exist in different temporal stages thereof. Public Library of Science 2015-05-29 /pmc/articles/PMC4449131/ /pubmed/26024484 http://dx.doi.org/10.1371/journal.pone.0128478 Text en © 2015 Vermathen et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Vermathen, Martina
Paul, Lydia E. H.
Diserens, Gaëlle
Vermathen, Peter
Furrer, Julien
(1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug
title (1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug
title_full (1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug
title_fullStr (1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug
title_full_unstemmed (1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug
title_short (1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug
title_sort (1)h hr-mas nmr based metabolic profiling of cells in response to treatment with a hexacationic ruthenium metallaprism as potential anticancer drug
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449131/
https://www.ncbi.nlm.nih.gov/pubmed/26024484
http://dx.doi.org/10.1371/journal.pone.0128478
work_keys_str_mv AT vermathenmartina 1hhrmasnmrbasedmetabolicprofilingofcellsinresponsetotreatmentwithahexacationicrutheniummetallaprismaspotentialanticancerdrug
AT paullydiaeh 1hhrmasnmrbasedmetabolicprofilingofcellsinresponsetotreatmentwithahexacationicrutheniummetallaprismaspotentialanticancerdrug
AT diserensgaelle 1hhrmasnmrbasedmetabolicprofilingofcellsinresponsetotreatmentwithahexacationicrutheniummetallaprismaspotentialanticancerdrug
AT vermathenpeter 1hhrmasnmrbasedmetabolicprofilingofcellsinresponsetotreatmentwithahexacationicrutheniummetallaprismaspotentialanticancerdrug
AT furrerjulien 1hhrmasnmrbasedmetabolicprofilingofcellsinresponsetotreatmentwithahexacationicrutheniummetallaprismaspotentialanticancerdrug